Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00159731
Status:
COMPLETED
Last Update Posted:
2021-01-22
First Post:
2005-09-08
Brief Title:
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
An Open Label Extension Safety Trial of Pregabalin CI-1008 in Subjects With Diabetic Peripheral Neuropathy
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to 1 provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060 and 2 find out if pregabalin is safe at a dose of 600 mgday taken twice a day
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None